Positive Serologic Test for Hepatitis B Virus (HBV)
Hepatitis B virus infection
False-positive serologic test for hepatitis B virus
Suggested Additional Lab Testing
Acute hepatitis B
Patient is positive for IgM antibody to HBV core antigen.
Patient is usually positive for hepatitis B surface antigen and hepatitis B virus e antigen. Presence of the e antigen indicates a high degree of infectivity.
Patient is likely to be positive for serum HBV DNA; level can be followed to assess response to therapy.
Chronic hepatitis B
Liver function tests, especially aminotransferases, are likely to be elevated for more than 6 months.
Hepatitis B surface antigen is positive for more than 6 months.
Chronic cases are also positive for anti-HBV core antigen as total antibody or as IgG.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Patients and Caregivers Worry About Cost of Cancer Care
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- Opioid Shortage Influences How Cancer-Related Pain Is Managed by Inpatient Palliative Care Team
- Tumor Lysis Syndrome, Renal Failure Complicate Elotuzumab Therapy for Multiple Myeloma
- How to Help Patients at the End of Life and Their Loved Ones During the Holidays
- Real-World Prevalence of AEs With Immune Checkpoint Inhibitors for NSCLC Higher Than Reported in Trials
- Disparities Seen in Goals-of-Care Discussions With Minority vs Nonminority Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|